ALESIA
A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
- NCT02838420 ↗
- Completed
- Hoffmann-La Roche
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on ALESIA (alectinib in treatment-naive advanced ALK-positive non-small cell lung cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ALESIA so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 7 posts on X | |
| 1 podcast episode |
The trial
ClinicalTrials.gov- Official title
- Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Asian Patients With Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer
- Interventions
- Alectinib; Crizotinib
- Arms
- Alectinib · Experimental
- Crizotinib · Active comparator
- Enrollment
- 187
- Primary outcomes
- Progression-Free Survival (PFS) as Determined by Investigator Using Response Evaluation Criteria in Solid Tumor (RECIST) v1.1
- Sponsor
- Hoffmann-La Roche
- Start
- Aug 3, 2016
- Primary completion
- May 31, 2018
- Results posted
- Yes
- Registry record
- NCT02838420 · updated Jun 24, 2026
Publications
linked from the registry- Zhou C, Kim SW, Reungwetwattana T, Zhou J, Zhang Y, He J, Yang JJ, Cheng Y, Lee SH, Bu L, Xu T, Yang L, Wang C, Liu T, Morcos PN, Lu Y, Zhang L. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. Lancet Respir Med. 2019 May;7(5):437-446. doi: 10.1016/S2213-2600(19)30053-0. Epub 2019 Apr 10. PubMed 30981696